<DOC>
	<DOCNO>NCT01332526</DOCNO>
	<brief_summary>Fructose intake add sugar increase dramatically last century recently implicate potential contributor metabolic syndrome , obesity , hypertension , inflammation kidney disease . Fructose differs sugar , uric acid generate metabolism . Serum uric acid level find correlate intake fructose add sugar . In turn , elevate serum uric acid also show associate increase risk cardiovascular metabolic disease . On hand complexity fructose metabolism individual result various magnitude hyperuricemia induce fructose intake . The magnitude uric acid production patient may reflect individual predisposition endogenous urate production face relatively normal fast uric acid concentration . Therefore oral fructose tolerance test might reveal occult purine disturbance play casual role either metabolic disturbance organ damage . The aim study see whether relationship fructose induce hyperuricemia metabolic disturbance , inflammatory state organ damage obese various stage CKD patient .</brief_summary>
	<brief_title>FFT , Inflammation , Lipid Metabolism , Blood Pressure Organ Damage Patients With Obesity , Chronic Kidney Disease ( CKD ) .</brief_title>
	<detailed_description>The study perform two experimental group . Proposed study group Study I Patients BMI &gt; 30 metabolic syndrome . Patient BMI &gt; 30 without metabolic syndrome . Normal healthy control . Study II Patients CKD stage III uric acid &lt; 7 mg/dl Patients CKD stage III uric acid &gt; 7 mg/dl Patient asymptomatic hyperuricemia eGFR &gt; 90 ml/min/1.73 m2 , , uric acid &gt; 7 mg/dl Hemodialysis patient Characteristics particular patient group- include criterion : 10- 15 participant subset group age 18-65 . Gender : female male equal proportion . Group I Patients BMI &gt; 30 metabolic syndrome ( ATP III ) . Patient BMI &gt; 30 without metabolic syndrome . Normal healthy control- healthy person ( without renal disease , cardiovascular disease , diabetes mellitus , BMI &lt; 25 ; normotensives ) . Group II Patients CKD stage III ( GFR 30-59 ml/min/1,73 m2 ) uric acid &lt; 7 mg/dl . - without diabetes mellitus proteinuria &lt; 3,5 g/24 h without immunosuppressive agent , ACEi , ARB , allopurinol treatment well control hypertension ( &lt; 140/90 mmHg ) Patients CKD stage III ( GFR 30-59 ml/min/1,73 m2 ) uric acid &gt; 7 mg/dl - without diabetes mellitus proteinuria &lt; 3,5 g/24 h without immunosuppressive agent , ACEi , ARB , allopurinol treatment well control hypertension ( &lt; 140/90 mmHg ) Patient asymptomatic hyperuricemia , uric acid &gt; 7 mg/dl normal renal function Hemodialysis patient . - CKD : nondiabetic nephropathy - duration hemodialysis 3-48 month - Hb-11-13 g/dl - well control hypertension ( &lt; 140/90 mmHg ) - without ACEi , ARB , allopurinol treatment - residual diuresis estimate last 48 hours-between mid next dialysis Method investigation All patient control ( hemodialysis ) present overnight fast . Baseline test include 24 hr urine collection : sodium , calcium , phosphorus , creatinine , uric acid , NAG , albumin carry morning fast sample blood : creatinine , cystatin C , uric acid , sodium , glucose , insulin , triglyceride , HDL LDL cholesterol , calcium , phosphorus , hsCRP . BP determine mean three reading take 5 min apart sit . Next patient control fructose tolerance test perform . The test consist give 1 gram/kg b.w . fructose p.o . blood collection 0,30,60 120 min afterward serum uric acid determination uric acid area curve calculate . The calculated area curve measure occult uric acid disturbance compare control . Day urine collection ABPM , BMI , IM ( intima medium ratio ) , renal duplex ultrasound ( RI ) do Measure BMI , waist circumference</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Uric Acid</mesh_term>
	<criteria>Group I Patients BMI &gt; 30 metabolic syndrome ( ATP III ) . Patient BMI &gt; 30 without metabolic syndrome . Normal healthy control healthy person ( without renal disease , cardiovascular disease , diabetes mellitus , BMI &lt; 25 ; normotensives ) . Group II Patients CKD stage III ( GFR 3059 ml/min/1,73 m2 ) uric acid &lt; 7 mg/dl . without diabetes mellitus proteinuria &lt; 3,5 g/24 h without immunosuppressive agent , ACEi , ARB , allopurinol treatment well control hypertension ( &lt; 140/90 mmHg ) Patients CKD stage III ( GFR 3059 ml/min/1,73 m2 ) uric acid &gt; 7 mg/dl without diabetes mellitus proteinuria &lt; 3,5 g/24 h without immunosuppressive agent , ACEi , ARB , allopurinol treatment well control hypertension ( &lt; 140/90 mmHg ) Patient asymptomatic hyperuricemia , uric acid &gt; 7 mg/dl normal renal function Hemodialysis patient . CKD : nondiabetic nephropathy duration hemodialysis 348 month Hb1113 g/dl well control hypertension ( &lt; 140/90 mmHg ) without ACEi , ARB , allopurinol treatment residual diuresis estimate last 48 hoursbetween mid next dialysis immunosuppressive agent , ACEi , ARB , allopurinol treatment diabetes mellitus well control hypertension ( &gt; 140/90 mmHg ) proteinuria &gt; 3,5 g/24 h</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>FFT</keyword>
	<keyword>inflammation</keyword>
	<keyword>lipid metabolism</keyword>
	<keyword>hyperuricemia</keyword>
	<keyword>Agents Affecting Uric Acid Metabolism</keyword>
</DOC>